Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. - Wikidata - awgldk - TriplyDB

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

http://www.wikidata.org/entity/Q44920056

about

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A(1)-adenosine receptors to mediate antinociception.Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Advances in preclinical investigation of prostate cancer gene therapy.Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.Vaccines as monotherapy and in combination therapy for prostate cancer.Cancer immunotherapy: sipuleucel-T and beyond.Dendritic cell-based immunotherapy for prostate cancer.Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.A 60-kilodalton protein component of the counting factor complex regulates group size in Dictyostelium discoideum.A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response Proposed mechanisms of action for prostate cancer vaccines.Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.Management of high-risk localized prostate cancer.Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.Recent clinical development of dendritic cell-based immunotherapy for prostate cancer.Targeted therapies for prostate cancer.The current and emerging role of immunotherapy in prostate cancer The immunotherapy of prostate and bladder cancer.Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.Current perspectives in prostate cancer vaccines Sipuleucel-T (APC8015) for prostate cancer.Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.Therapeutic cancer vaccines: the latest advancement in targeted therapy.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Immunology and immunotherapy approaches for prostate cancer.Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015 Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).Human prostatic acid phosphatase: structure, function and regulation.Rebuilding immunity in cancer patients.Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.Tissue vaccines for cancer.Promising novel immunotherapies and combinations for prostate cancer Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

P2860

Q27008070-0B0A1F88-EA88-467F-8111-200F5C817403 Q33401583-9ACF8F6C-4D38-410D-8911-B252D0F26A3A Q33653836-86C15FFA-EAB5-41AC-AF85-C4E042827491 Q33677054-94B1E62D-B5E1-46BE-A5B8-6071592E653C Q33740816-B20B07D3-D8C0-4353-B699-4E3F8007349F Q34039068-6D96EC1A-3517-4CCF-8F61-E01E80AECA41 Q34158070-9DF6389F-1EA0-4F5F-B49D-807632EEC1C1 Q34284652-94FA6903-553F-4A78-A450-06600D55A884 Q34290252-E504F984-0808-46EA-8D62-152826955AE6 Q34906723-58B27207-F6BE-483A-A515-DFA59D165F04 Q35023430-E7E54AFE-AE0B-4A7C-8B2E-9173D04A9BB8 Q35077524-6F323188-AF65-4ADA-92F1-90FB79A96EF1 Q35174754-EF57A247-B4F1-447C-8F6A-D51852E77561 Q35218994-9E9ACF81-F32D-41A4-A4A5-94E4873963D2 Q35503645-4C851121-9B56-4184-B0B9-E14807A6CE21 Q35510910-029676F9-6F95-4B0F-A8AA-35144DAD1E28 Q35584269-0385C247-6C73-46CD-947F-6CCA29BA652B Q35758285-F0F2023A-AC57-4E5C-A121-8465FFC4DCBE Q35925600-AC00F146-FB2F-4D27-9C9C-AD8A08BEAF4F Q36150842-F1F7EE5B-5B02-4F0A-897C-04DD86D97343 Q36249922-6FFD95BB-BE49-4ADB-894B-899EE7CA6F3B Q36249962-09489A8C-8460-48F1-BB48-484B6972EC0B Q36258513-FB3918FD-3F74-459C-8FA0-8DC8CDDEB529 Q36272854-54C2E7F1-39A2-481B-96F2-33F9F7325F7C Q36285594-D0099104-7123-4822-8D40-7AAEE70997CA Q36317185-4F66381B-8E00-4F7A-B0E9-B344B83B847C Q36613961-9322D288-207B-4389-BFA3-7B20A8901690 Q36642308-6F844188-C452-4942-8825-AF05805B6AEA Q36695629-5103A288-F298-4A97-9BAD-3A93636F6FAF Q36708792-687A3D24-6F38-4255-B27A-4C9F638C2F0B Q36786512-2EBD5978-02EA-4E97-85C7-2C512D85AF89 Q36822947-A3C4CBE3-FEBC-4B28-8C39-4DFF0327C945 Q36909396-5F8BCCF2-FEC6-4EAE-A2BE-B7664F62A29D Q36913762-FD9EDEF1-4A2C-45E8-93E1-78AA0DBC7F46 Q36934947-73DF1220-9EC6-4277-9ECA-11638215CFC0 Q37038179-A1E3BC16-4931-45D1-8034-1AC58CF83A4E Q37118188-F3C66CF5-0B7F-4B0D-A20A-9939334D7506 Q37123446-CEAF2FD5-4750-461D-9E82-510F60ECC377 Q37250456-C9BD95FB-1F60-47BC-A2A4-02203C476F0F Q37281267-8201D020-1016-490C-9568-03A270719CAC

P2860

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

http://www.wikidata.org/entity/Q44920056

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@en

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@nl

type

label

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@en

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@nl

prefLabel

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@en

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@nl

P1433

Q44920056-C4211C9D-6BEB-47FA-A3BB-433D20F3598C

P1476

Q44920056-2501E0F1-BA02-4437-8195-81529A7994A4

P2093

Q44920056-2F464E92-17DB-4EE9-9BD0-334B223BA49B

Q44920056-40AF229C-DC6A-4CA7-BA8A-72D93B092AE6

Q44920056-564F3358-46F7-406C-A0CB-627625EDF117

Q44920056-5A0EAE74-D36F-46C7-A735-5E6EF36BDA8A

Q44920056-8EC0603A-D276-48A9-B7B6-DE690D22F593

Q44920056-90656E43-CB03-475C-8293-FDFCDB3573B9

Q44920056-ADEBFB66-14BE-4C80-BEAF-A18117045864

Q44920056-B5E04706-FECE-487E-96A2-53BA8B120646

Q44920056-E8A8220E-CDE8-4BEC-94BD-868A62DEFC8E

P2860

Q44920056-56D760F9-673D-445E-8A40-D07A64E1AB99

Q44920056-69E04578-A509-45C9-9557-BD93DC9C2C13

Q44920056-8492390E-8A2A-48DB-8106-5302190C17CD

Q44920056-AF39888A-B3C1-41F6-97CE-FE7722AAD7BE

Q44920056-B84F3686-0132-4900-917A-D8600A4B7AA3

Q44920056-C2766B8B-A0F3-4DA5-9887-F50CF41935CB

Q44920056-C78514F9-E635-44BB-870D-657017B80695

Q44920056-CCA6518C-384C-4696-9E60-839AD6D4BB4A

P304

Q44920056-87DCE369-73CF-4456-B7F0-2A9D014273B6

P31

Q44920056-AD443159-8B29-41EF-BA4F-9F802F6C1A68

P356

Q44920056-1DCD9F54-D666-4C2D-BCC9-5F73D7B84D4F

P433

Q44920056-868EDBCF-603A-4228-8218-E6267C026BCA

P478

Q44920056-8FFFF0BA-6DE5-4FE7-A883-AC7521CCBC1C

P577

Q44920056-F6145B87-39F9-42B6-8449-8570E715B632

P698

Q44920056-A835E85B-28AA-497B-A049-D1B26CFE35FF

P921

Q44920056-064CE4F9-0CB7-4F5F-AB04-A9BCA599D79B

Q44920056-C5CEC206-D85E-40FA-90B0-A201C39D62E0

P356

P1433

P1476

Immunotherapy (APC8015, Proven ...... state cancer: a Phase 2 trial.

@en

P2093

Dennis A Gastineau

http://www.w3.org/2001/XMLSchema#string

Frank H Valone

http://www.w3.org/2001/XMLSchema#string

Gary A Croghan

http://www.w3.org/2001/XMLSchema#string

Jelle W Kylstra

http://www.w3.org/2001/XMLSchema#string

Judith S Kaur

http://www.w3.org/2001/XMLSchema#string

Lori A Jones

http://www.w3.org/2001/XMLSchema#string

Patrick A Burch

http://www.w3.org/2001/XMLSchema#string

Ronald L Richardson

http://www.w3.org/2001/XMLSchema#string

Stanimir Vuk-Pavlović

http://www.w3.org/2001/XMLSchema#string

P2860

Dendritic cells and the control of immunity

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Dendritic cells: On the move from bench to bedside.

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

P304

197-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.20040

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15176049

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial